Giancarlo Bisagni

6PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.

Benedetta Conte, Luca Boni, Giancarlo Bisagni

|Oct 19, 2023
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Benedetta Donati, Francesca Reggiani, Federica Torricelli

|Sep 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.

PierFranco Conte, Giancarlo Bisagni, Federico Piacentini

|Sep 07, 2023
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.

Maria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni

|Jul 07, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.

Federica Miglietta, Moira Ragazzi, Bethania Fernandes

|Mar 20, 2023
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

Grazia Vernaci, Edoardo Vincenzo Savarino, Ilaria Patuzzi

Pageof 1

Frequent Collaborators

4 joint publications

Maria Vittoria Dieci

4 joint publications

Valentina Guarneri

3 joint publications

Federica Miglietta

3 joint publications

Gaia Griguolo